{
    "nctId": "NCT00190593",
    "briefTitle": "Raloxifene Use for The Heart",
    "officialTitle": "Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events",
    "overallStatus": "COMPLETED",
    "conditions": "Cardiovascular Diseases, Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 10000,
    "primaryOutcomeMeasure": "Time to first occurrence of coronary death, non-fatal myocardial infarction (MI), or hospitalized acute coronary syndrome other than MI combined after an expected 5 to 7.5 years of follow-up.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with established coronary heart disease or at risk for a major coronary event.\n\nExclusion Criteria:\n\n* Postmenopausal symptoms that required estrogen replacement therapy.\n* Suspected or known history of breast or endometrial carcinoma.\n* Known or probable history of deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis.\n* New York Heart Association classes III or IV heart failure.",
    "sex": "FEMALE",
    "minimumAge": "55 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}